In a retrospective study comprising of patients with hand eczema, Dupilumab demonstrated unparalleled efficacy and superior safety profile across all the evaluation points, marking a paradigm shift in hand eczema management. Notably, within just 6 weeks of treatment, over half of the patients achieved Hand Eczema Severity Index (HECSI) HECSI-75, a key marker of disease improvement.

Hand eczema or dermatitis, is a chronic skin disease that plagues millions throughout the world which negatively affects the quality of life. There are limited treatment options for eczema, one such being Alitretinoin but its high cost and side effect profile restrict its use. 

In a total of 21 individuals suffering from hand dermatitis, the use of Dupilumab by week 16 led to an astounding 90% of patients fulfilling the HECSI-75 criteria, a figure that soared to 100% by week 104 (details in Figure 1). A majority of patients achieved HECSI-90 and HECSI-100, indicating near-complete resolution of symptoms.

Undoubtedly, Dupilumab, with its excellent safety profile, emerges as the optimal choice for achieving disease clearance effectively, as concluded.